The Company’s current research and development pipeline includes two products based on the novel natural oestrogen Estetrol (E4) as well as three complex therapeutic solutions.
Mithra’s lead drug candidate, Estelle®, is a combined oral contraceptive (COC), composed of 15 mg of E4 and 3 mg of DRSP. Estelle® is currently under phase III clinical trials.
Donesta® is a new generation of hormone replacement therapy (HRT) with the oral administration of E4 for VMS. Donesta® is currently under clinical phase II trial.
Complex therapeutic solutions
Under « Complex therapeutic solutions » Mithra classifies products which do not respond to the typical profile of a generic product.